BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 3.11.1999

Draft ``Guidance for Industry: Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors;'' Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance document entitled ``Guidance for Industry: Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors.'' The draft guidance document applies to the manufacture of gene therapy retroviral vector products intended for in vivo or ex vivo use and to followup monitoring of patients who have received retroviral vector products. When finalized, the draft guidance document is intended to supplement the guidance document entitled ``Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy,'' dated March 1998, and a letter to Sponsors of an IND Using Retroviral Vectors, dated September 20, 1993.

Source: Federal Register — Food and Drug AdministrationOpen original release →